In a moment when trade policy and national resilience have become inseparable, Eli Lilly has committed $27 billion to build four pharmaceutical manufacturing plants on American soil — a decision shaped as much by political pressure as by the company's own strained capacity. The Indianapolis-based drugmaker, whose weight-loss medications have outpaced the world's ability to produce them, is betting that the era of offshored pharmaceutical chemistry is ending. It is a wager placed at the intersection of tariff threats, tax incentives, and a deeper reckoning about what a nation owes itself in tim
Eli Lilly announces $27B US manufacturing push amid Trump tariff threats
Every machine isn't working at Lilly right now, and that's not sustainable
Mark
So Eli Lilly is spending $27 billion on new plants. Is that because they genuinely need the capacity, or because Trump is threatening tariffs?
Mimi
Both, actually. The demand for Zepbound and Mounjaro is real—they've been in shortage for two years. But Ricks was explicit that the tariff environment accelerated the timeline. He said they're running every machine 24/7 right now, which isn't sustainable.
Luke
But here's the thing: Ricks also said the whole plan depends on renewing the Tax Cuts and Jobs Act. So if that doesn't happen, the investment might not either. That's a pretty big conditional.
Mark
What about the locations? Are they announced yet?
Mimi
No, they're still negotiating with states. The deadline for interest is March 12. The company estimates 13,000 jobs across manufacturing and construction.
Luke
That's a projection, though. We don't know yet if those jobs materialize or what the actual wage levels will be. It's worth noting the difference between announced investment and actual hiring.
Mark
What about the drugs themselves? Is Lilly developing anything new?
Mimi
They're testing orforglipron, a pill version, with results expected in a few months. And there's retatrutide, which Ricks called the next generation of weight-loss drugs.
Luke
Those are still in trials. The orforglipron results haven't come back yet, so we're talking about future products, not current ones.
Mark
And Kennedy—the health secretary—he's been skeptical of these drugs, right?
Mimi
Mixed signals. He called them "miracle drugs" at his confirmation hearing but also said they shouldn't be first-line treatment for kids. Though he was factually wrong about the approved age—they start at 12, not 6.
Luke
That's important to flag because it shows Kennedy may not be fully informed on the details, even as he's shaping health policy. Ricks seems optimistic about working with him, but that's one executive's read.
Der Puls
- President Trump's threatened 25% tariffs on pharmaceutical imports — potentially arriving as early as April — have forced one of America's largest drugmakers to accelerate a reshoring strategy it might otherwise have taken decades to complete.
- Eli Lilly's global manufacturing is already running at its absolute limit, with every machine operating around the clock just to meet demand for Zepbound and Mounjaro — a pace the CEO calls unsustainable and dangerous.
- The $27 billion commitment hinges on a political condition: if the Tax Cuts and Jobs Act is not renewed and the corporate tax rate climbs back toward 35%, Ricks says the entire plan would have to be reconsidered.
- Thirteen thousand jobs and four new plants are promised, but no locations have been chosen yet — states are competing for the facilities, with a deadline of March 12 to make their case.
- Beyond business logic, Lilly's CEO is sounding an alarm about national vulnerability, warning that America has effectively lost the domestic capacity for small-molecule drug synthesis — the chemical backbone of most oral medications.
In a moment when trade policy and national resilience have become inseparable, Eli Lilly has committed $27 billion to build four pharmaceutical manufacturing plants on American soil — a decision shaped as much by political pressure as by the company's own strained capacity. The Indianapolis-based drugmaker, whose weight-loss medications have outpaced the world's ability to produce them, is betting that the era of offshored pharmaceutical chemistry is ending. It is a wager placed at the intersection of tariff threats, tax incentives, and a deeper reckoning about what a nation owes itself in times of crisis.
Eli Lilly announced Wednesday a $27 billion commitment to build four new manufacturing plants across the United States, a move its leadership tied directly to President Trump's threatened tariffs on pharmaceutical imports and mounting political pressure to bring drug production back home. Three of the facilities will produce active pharmaceutical ingredients — the chemical foundations of medicines — while a fourth will manufacture injectable products. Together, they are expected to create roughly 13,000 jobs and begin operations within five years.
CEO David Ricks was candid about the forces driving the decision. "The policy environment is a major contributor," he told CNN, adding that if tariffs take hold broadly, most industries will face similar pressure to reshore investment. He also flagged a critical condition: the entire plan depends on renewal of the Tax Cuts and Jobs Act, which lowered the corporate tax rate to 21%. Without that extension, he said, the company would have to reconsider.
The announcement arrives against a backdrop of genuine strain. Lilly's revenue surged 32% to $45 billion last year, fueled almost entirely by its diabetes and weight-loss drugs, which spent two years in shortage as demand overwhelmed supply. Ricks described the company's global plants as running "24/7, 365 — there's not a single hour of any day that every machine isn't working." The new facilities are meant to relieve that pressure while also building redundancy into a supply chain he called dangerously fragile.
Ricks framed the investment in terms of national security as well as commerce, warning that America has effectively lost domestic capacity for small-molecule drug synthesis — the chemistry behind most oral tablets. He suggested that with three large new ingredient plants, Lilly could potentially redirect capacity during a pandemic or other national emergency.
Lilly has not yet chosen locations for the four plants. States have until March 12 to submit expressions of interest. The $27 billion adds to $50 billion in total manufacturing investments the company has pledged since 2020 — a cumulative shift in how one of the world's largest pharmaceutical companies thinks about where, and why, it makes its medicines.
Eli Lilly announced Wednesday that it would spend $27 billion to build four new manufacturing plants across the United States, a dramatic acceleration of domestic production that the company's leadership tied directly to President Trump's threatened tariffs on pharmaceuticals and the broader political pressure to move drug manufacturing back home.
Three of the facilities will produce active pharmaceutical ingredients—the chemical foundation of medicines—while the fourth will manufacture injectable products. The Indianapolis-based company, which makes the blockbuster weight-loss drugs Zepbound and Mounjaro, said the plants are expected to begin operations within five years and will create approximately 13,000 jobs in manufacturing and construction. The announcement comes as Trump has signaled his intention to impose tariffs around 25% on pharmaceutical imports starting as early as April 2, and after he met privately with drug industry executives last week to urge them to shift production to American soil.
David Ricks, Eli Lilly's chief executive, told CNN that the company wanted to build manufacturing redundancy and strengthen its supply chain, but he was direct about the political calculus driving the decision. "The policy environment is a major contributor," he said, noting that if the Trump administration's tariff plans succeed, "you could see where most industries will need to reshore a lot of investment." Ricks, who attended the White House meeting, added that the company was moving quickly because he anticipated constraints across building materials and energy supplies as other industries made similar moves. He emphasized, however, that the entire plan depends on renewal of the Tax Cuts and Jobs Act from Trump's first term, which lowered the corporate tax rate to 21% from 35%. Without that extension, he said, the company would have to reconsider the investment.
Lilly's revenue grew 32% to $45 billion last year, driven almost entirely by demand for its diabetes and weight-loss medications. Both Zepbound and Mounjaro, along with competing drugs like Novo Nordisk's Ozempic and Wegovy, spent two years in shortage as demand far outpaced supply. Ricks described the current state of the company's global manufacturing as unsustainable: "Right now, for good or bad, we're running our plants globally 24/7, 365. There's not a single hour of any day that every machine isn't working at Lilly right now." He said the company is struggling to keep up with what he called "runaway demand" while still performing necessary maintenance.
The company has not yet determined where the four plants will be located. Lilly said it is in negotiations with several states and will accept expressions of interest through March 12. This $27 billion commitment adds to the $50 billion in total manufacturing investments the company has pledged since 2020, representing a fundamental shift in how the company sources its production.
Ricks framed the investment partly as a matter of national security and resilience. He noted that while much of the pharmaceutical industry's reliance on imports comes from China and India for generic drugs—which Lilly does not manufacture—the company has concerns about the loss of domestic capacity for small-molecule drug synthesis, the chemistry-based manufacturing process used for oral tablets. "It's dangerous for our country to have offshored production for whole types of technology like small-molecule synthesis, which is really not happening in our country at all anymore," he said. With three massive new plants, he suggested, the company could potentially repurpose capacity during a pandemic or other crisis.
Lilly is also developing next-generation weight-loss medications. The company is testing a pill called orforglipron, with late-stage trial results expected within three months, and another drug called retatrutide that Ricks described as "sort of the next super weight-loss drug from Lilly." He positioned these medicines as aligned with the Trump administration's health priorities, particularly the "Make America Healthy Again" agenda championed by Health Secretary Robert F. Kennedy Jr. "What could be more important than controlling obesity?" Ricks said. "It's probably the single biggest lever that exists" for improving health outcomes.
Kennedy's stance on obesity drugs has been inconsistent. In October, he criticized drugmakers for selling the medications to Americans, saying they do so "because we're so stupid and addicted to drugs." During his confirmation hearings, he called them "miracle drugs" but expressed concern about their use in children, making a factually incorrect claim that they are currently approved for six-year-olds when the actual approved age is 12. When asked about his interactions with Kennedy, Ricks said he found him to be "a good listener" and "hungry for information," and expressed confidence that the company could collaborate with the administration on obesity treatment while pushing back where the science demanded it.
Bemerkenswerte Zitate
The policy environment is a major contributor to the plans. If the wishes of this administration come true, you could see where most industries will need to reshore a lot of investment.— David Ricks, Eli Lilly CEO
It's dangerous for our country to have offshored production for whole types of technology like small-molecule synthesis, which is really not happening in our country at all anymore.— David Ricks, Eli Lilly CEO
Möchten Sie die ganze Geschichte?
Das Original lesen bei Cable News Network ↗
Health & Medicine